Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar User Fee Forecast: Unchanged Or Lower In FY 2019, US FDA Says

Executive Summary

Absence of any fee increases reflects growing numbers of both approved biosimilars and products under development, as well as agency’s commitment to start spending down some of the carryover balance from prior years’ fee collections.

Advertisement

Related Content

Biosimilars At US FDA: Personnel Spending Losing Influence Over Program
Biosimilars At US FDA: Personnel Spending Losing Influence Over Program
PDUFA Becomes US FDA's Billion Dollar Baby
ANDA Submissions To US FDA Expected To Decline; Generic User Fees For FY 2019 Will Rise
US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals
The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees
Pending Biosimilars
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
User Fees For FY 2017 Make Sponsors Happy, Manufacturers Sad

Topics

Advertisement
UsernamePublicRestriction

Register

PS123595

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel